Biofrontera Inc [NASDAQ: BFRI] surged by $0.4 during the normal trading session on while it closed the day at $1.15. The company report on February 20, 2024 at 8:10 AM that Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG.
Ameluz ® transfer price to Biofrontera AG reduced significantly.
Control of all US clinical trials of Ameluz transfers to Biofrontera Inc. on June 1.
Biofrontera Inc stock has also gained 61.97% of its value over the past 7 days. However, BFRI stock has declined by -69.66% in the 3 months of the year. Over the past six months meanwhile, it has lost -87.70% and lost -58.48% year-on date.
The market cap for BFRI stock reached $1.58 million, with 1.33 million shares outstanding and 1.03 million shares in the current float. Compared to the average trading volume of 245.46K shares, BFRI reached a trading volume of 28393759 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Biofrontera Inc [BFRI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BFRI shares is $20.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BFRI stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Biofrontera Inc is set at 0.25, with the Price to Sales ratio for BFRI stock in the period of the last 12 months amounting to 0.05. The Price to Book ratio for the last quarter was 1.52, with the Price to Cash per share for the same quarter was set at 4.93.
BFRI stock trade performance evaluation
Biofrontera Inc [BFRI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 61.97. With this latest performance, BFRI shares dropped by -29.88% in over the last four-week period, additionally sinking by -87.70% over the last 6 months – not to mention a drop of -92.98% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BFRI stock in for the last two-week period is set at 43.24, with the RSI for the last a single of trading hit 57.02, and the three-weeks RSI is set at 37.61 for Biofrontera Inc [BFRI]. The present Moving Average for the last 50 days of trading for this stock 2.0848, while it was recorded at 0.7954 for the last single week of trading, and 6.6987 for the last 200 days.
Biofrontera Inc [BFRI]: An insightful look at the core fundamentals
Biofrontera Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.47 and a Current Ratio set at 1.02.
Earnings per share (EPS) analysis for Biofrontera Inc [BFRI] stock
With the latest financial reports released by the company, Biofrontera Inc posted -2.8/share EPS, while the average EPS was predicted by analysts to be reported at -2.2/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -27.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BFRI.
Biofrontera Inc [BFRI]: Institutional Ownership
The top three institutional holders of BFRI stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in BFRI stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in BFRI stock with ownership which is approximately 5.8325%.
